These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 9353611)
1. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Kamath V; Jones CN; Yip JC; Varasteh BB; Cincotta AH; Reaven GM; Chen YD Diabetes Care; 1997 Nov; 20(11):1697-701. PubMed ID: 9353611 [TBL] [Abstract][Full Text] [Related]
2. Chronic physiologic hyperinsulinemia impairs suppression of plasma free fatty acids and increases de novo lipogenesis but does not cause dyslipidemia in conscious normal rats. Koopmans SJ; Kushwaha RS; DeFronzo RA Metabolism; 1999 Mar; 48(3):330-7. PubMed ID: 10094109 [TBL] [Abstract][Full Text] [Related]
3. Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women. Kok P; Roelfsema F; Frölich M; van Pelt J; Stokkel MP; Meinders AE; Pijl H Am J Physiol Endocrinol Metab; 2006 Nov; 291(5):E1038-43. PubMed ID: 16803851 [TBL] [Abstract][Full Text] [Related]
4. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815 [TBL] [Abstract][Full Text] [Related]
5. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Jeppesen J; Zhou MY; Chen YD; Reaven GM Diabetes Care; 1994 Oct; 17(10):1093-9. PubMed ID: 7821127 [TBL] [Abstract][Full Text] [Related]
6. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367 [TBL] [Abstract][Full Text] [Related]
8. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels. Krysiak R; Okopien B Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):251-6. PubMed ID: 25123447 [TBL] [Abstract][Full Text] [Related]
9. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Cincotta AH; Meier AH Diabetes Care; 1996 Jun; 19(6):667-70. PubMed ID: 8725871 [TBL] [Abstract][Full Text] [Related]
10. Meal frequency; does it determine postprandial lipaemia? Murphy MC; Chapman C; Lovegrove JA; Isherwood SG; Morgan LM; Wright JW; Williams CM Eur J Clin Nutr; 1996 Aug; 50(8):491-7. PubMed ID: 8863008 [TBL] [Abstract][Full Text] [Related]
11. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Oakes ND; Thalén PG; Jacinto SM; Ljung B Diabetes; 2001 May; 50(5):1158-65. PubMed ID: 11334421 [TBL] [Abstract][Full Text] [Related]
12. Effects of hyperglycaemia and hyperinsulinaemia on plasma amino acid levels in obese subjects with normal glucose tolerance. Marchesini G; Bianchi G; Rossi B; Muggeo M; Bonora E Int J Obes Relat Metab Disord; 2000 May; 24(5):552-8. PubMed ID: 10849575 [TBL] [Abstract][Full Text] [Related]
14. Metabolic changes following sibutramine-assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistance of obesity. McLaughlin T; Abbasi F; Lamendola C; Kim HS; Reaven GM Metabolism; 2001 Jul; 50(7):819-24. PubMed ID: 11436188 [TBL] [Abstract][Full Text] [Related]
15. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Cincotta AH; Meier AH; Cincotta M Expert Opin Investig Drugs; 1999 Oct; 8(10):1683-1707. PubMed ID: 11139820 [TBL] [Abstract][Full Text] [Related]
16. Insulin sensitivity indices of glucose and free fatty acid metabolism in obese children and adolescents in relation to serum lipids. Reinehr T; Kiess W; Andler W Metabolism; 2005 Mar; 54(3):397-402. PubMed ID: 15736120 [TBL] [Abstract][Full Text] [Related]
17. Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus. Annuzzi G; De Natale C; Iovine C; Patti L; Di Marino L; Coppola S; Del Prato S; Riccardi G; Rivellese AA Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2397-402. PubMed ID: 15458975 [TBL] [Abstract][Full Text] [Related]
18. Effects of systemic delivery of insulin on plasma lipids and lipoprotein concentrations in pancreas transplant recipients. Katz HH; Nguyen TT; Velosa JA; Robertson RP; Rizza RA Mayo Clin Proc; 1994 Mar; 69(3):231-6. PubMed ID: 8133660 [TBL] [Abstract][Full Text] [Related]
19. Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. Rivellese AA; De Natale C; Di Marino L; Patti L; Iovine C; Coppola S; Del Prato S; Riccardi G; Annuzzi G J Clin Endocrinol Metab; 2004 May; 89(5):2153-9. PubMed ID: 15126535 [TBL] [Abstract][Full Text] [Related]
20. Relationship between insulin resistance, weight loss, and coronary heart disease risk in healthy, obese women. McLaughlin T; Abbasi F; Kim HS; Lamendola C; Schaaf P; Reaven G Metabolism; 2001 Jul; 50(7):795-800. PubMed ID: 11436184 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]